AbbVie, Besins must pay $448 million in FTC AndroGel case, judge rules

Washington, D.C. (July 3, 2018) -- AbbVie and Besins Healthcare violated antitrust law by filing sham patent litigation to delay the availability of generic AndroGel, a Philadelphia federal judge ruled Friday, ordering the companies to pay $448 million in disgorgement....

Related Sections